STENTiT

STENTiT is a Dutch medical device startup with a mission to regenerate arteries from the inside-out. Founded in 2017 as a spin-off from the Eindhoven University of Technology, the company focuses on developing regenerative endovascular implants. These bioresorbable devices aim to trigger a natural healing response by the circulating blood cells, ultimately being replaced by new vascular tissue to restore the artery. Since its inception, STENTiT has garnered international recognition and awards for its high-potential approach. The company recently secured a €1.80M Seed Round investment on 25 April 2022 from notable investors including BOM Brabant Ventures, NextGen Ventures, and Ten Cate Investeringsmaatschappij. With its current momentum, STENTiT aims to establish itself as the new standard in endovascular treatment, providing a long-term solution for millions of patients globally. As the company progresses through the translational phases, it holds the promise of making a significant impact in the medical device industry.